Profil
Dr. Richard Auburn is on the Board of Directors at Singula Bio Ltd.
Dr. Auburn was previously employed as a Principal Licensing & Ventures Manager by Oxford University Innovation Ltd.
He received his undergraduate degree from the University of Aberdeen and a graduate degree from the University of Cambridge.
Aktive Positionen von Richard Auburn
| Unternehmen | Position | Beginn |
|---|---|---|
Singula Bio Ltd.
Singula Bio Ltd. BiotechnologyHealth Technology Develops novel neoantigen-based cell therapies for cancer | Direktor/Vorstandsmitglied | 01.11.2020 |
Ehemalige bekannte Positionen von Richard Auburn
| Unternehmen | Position | Ende |
|---|---|---|
Oxford University Innovation Ltd.
Oxford University Innovation Ltd. Investment ManagersFinance Oxford University Innovation invests in spun out companies located in the United Kingdom. The firm targets companies operating in the fields of across a broad range of sectors and industries. It provides financing for seed and early-stage capital requirements. | Private Equity Investor | 01.06.2024 |
Ausbildung von Richard Auburn
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
University of Aberdeen
University of Aberdeen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oxford University Innovation Ltd.
Oxford University Innovation Ltd. Investment ManagersFinance Oxford University Innovation invests in spun out companies located in the United Kingdom. The firm targets companies operating in the fields of across a broad range of sectors and industries. It provides financing for seed and early-stage capital requirements. | Finance |
Singula Bio Ltd.
Singula Bio Ltd. BiotechnologyHealth Technology Develops novel neoantigen-based cell therapies for cancer | Health Technology |
















